These studies indicate a major role for bFGF in the mediation of the tumor suppressive effects of piroxicam in canine patients and suggest future benefits of using FGFR inhibitors in dogs with BlCa. This evidence concerns the gene FGF2 and bladder transitional cell carcinoma.